Reports Q4 revenue $105,000, consensus $510,000. "2022 was a productive year for Viridian, as we made significant progress and reached multiple important milestones in our TED program with VRDN-001, our lead product candidate. Building on this positive momentum, we are strategically positioned to continue the advancement of our pipeline of TED programs in 2023," said Scott Myers, President and CEO of Viridian Therapeutics. "As part of my recent appointment as CEO, I look forward to advancing our recently initiated THRIVE Phase 3 trial of VRDN-001 in patients with active TED, generating data in patients with chronic TED, continuing the development of our subcutaneous programs, and beginning to establish our commercial capabilities. These activities support our overall goal to build a fully integrated biopharmaceutical company."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VRDN:
- Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Viridian Therapeutics to participate in a conference call with JMP Securities
- Viridian Appoints Scott Myers as President and Chief Executive Officer
- Viridian Therapeutics appoints Scott Myers as President, CEO
